SCHEMBL5475932

SCHEMBL5475932

N#Cc1cccnc1N1CCN(C(=O)/C=C/c2cccc(Cl)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.59
HDAC2 Q92769 1/20 0.55
MAPT P10636 2/20 0.52
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
PANK3 Q9H999 1/20 0.48
ITGB2 P05107 1/20 0.48
ICAM1 P05362 1/20 0.48
ITGAL P20701 1/20 0.48
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 1/20 0.47
RECQL P46063 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475934 1.00 ENPP2 (0.59) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5486984 0.89 L3MBTL1 (0.53) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5486990 0.89 L3MBTL1 (0.53) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5481413 0.88 LMNA (0.52) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5480821 0.88 KDM4E (0.55) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5480813 0.88 KDM4E (0.55) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5481406 0.88 LMNA (0.52) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5486556 0.88 L3MBTL1 (0.69) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5486563 0.88 L3MBTL1 (0.69) ENPP2HDAC2MAPTGAAL3MBTL1
SCHEMBL5485406 0.87 L3MBTL1 (0.50) ENPP2MAPTGAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US claimed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists GRM5, GRM1, GRM3 ENPP2 2635/4885HDAC2 772/4885MAPT 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.